Endocrinology

Thyroid Cancer   

Questions discussed in this category



What is your evaluation approach for RAI response?  What cumulative dose do you use in practice for deciding a patient is RAI refractory?

Would you consider it for a patient with good PS but with limited metastatic disease? What dose fractionation would you prefer?


Papers discussed in this category


Cancer discovery, 2015-07

J Immunother Cancer,

Thyroid : official journal of the American Thyroid Association, 2020 May 07

Journal of thyroid research, 2020 Apr 14